[{"id":"b1b94d83-741f-4d5c-9a33-86ea9ee644b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05248685","created_at":"2022-02-21T13:52:42.675Z","updated_at":"2024-07-02T16:36:16.849Z","phase":"Phase 1","brief_title":"Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT05248685","lead_sponsor":"Beijing Boren Hospital","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Dual CD33/CLL1 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/17/2022","start_date":" 01/17/2022","primary_txt":" Primary completion: 01/17/2023","primary_completion_date":" 01/17/2023","study_txt":" Completion: 01/17/2024","study_completion_date":" 01/17/2024","last_update_posted":"2022-02-21"}]